Clinical trials: Cholangiocarcinomas
Intrahepatic Cholangiocarcinoma
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Southeast Asia and China have the highest incidence of intrahepatic cholangiocarcinoma worldwide, with limited treatment options and large unmet medical needs.
- Trial name
- NCT06375642
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
This is single-arm, observational, academic, investigator-driven study investigating the efficacy of liver transplantation after successful and sustained downstaging/tumor control of liver-limited unresectable intrahepatic…
- Trial name
- iCOLA (NCT06862934)
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cholangiocarcinoma
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy.
- Trial name
- PrE0204 (NCT02181634)
- Testing
- Nab-Paclitaxel and Gemcitabine
- Where
- 25 sites in United States, Austria
- Volunteers
- 74 people
- Sponsor
- PrECOG, LLC.
Biliary Tract Cancer, Portal Vein Embolization
Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma
Portal vein embolization is often recommended to reduce the risk of postoperative liver failure and mortality. In this retrospective cohort study, researchers investigated the effect of portal vein embolization in patients with…
- Trial name
- NCT06222619
- Testing
- Potal vein embilization
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Seoul National University Hospital
Pancreatic Cancer, Bile Duct Cancer
Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy
The purpose of this study is to clarify whether resecting pylorus-ring decreases delayed gastric emptying after pancreaticoduodenectomy and improves postoperative quality of life (QOL).
- Conditions
- Pancreatic Cancer, Bile Duct Cancer, Ampullary Cancer, Duodenal Cancer
- Trial name
- NCT00639314
- Testing
- pylorus-preserving pancreaticoduodenectomy, pylorus-resecting pancreaticoduodenectomy
- Where
- Japan
- Volunteers
- 130 people
- Sponsor
- Wakayama Medical University
Cholangiocarcinoma, Hepatocellular Carcinoma
In Vitro Models of Liver and Pancreatic Cancer
The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue.
- Conditions
- Cholangiocarcinoma, Hepatocellular Carcinoma, Pancreatic Neoplasm
- Trial name
- NCT02436564
- Testing
- Organoid in vitro culture
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Incidence of Cholangiocarcinoma on Choledochal Cysts, Postoperative Complications in Choledochal Cysts
Analysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center
Choledochal cysts are congenital cystic dilatations of the intra and/or extrahepatic bile duct. They have been considered a rare entity of the child population.
- Conditions
- Incidence of Cholangiocarcinoma on Choledochal Cysts, Postoperative Complications in Choledochal Cysts, Choledochal Cyst Monitoring
- Trial name
- QuiCo (NCT05404503)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- María Teresa Moreno Asencio
Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial…
- Conditions
- Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
- Trial name
- NCT06849180
- Testing
- Interventional therapies combined with or without systemic drugs
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Zhongda Hospital
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Cholangiocarcinoma
Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma
The purpose of this study is to compare endoscopic radiofrequency ablation with photodynamic therapy for inoperable cholangiocarcinoma
- Trial name
- NCT01739465
- Testing
- Self expanding metallic stent (SEMS), Endoscopic radiofrequency ablation (ERFA), Photodynamic therapy (PDT)
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Guangzhou Medical University
Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
This randomized phase I trial is studying the side effects and best dose of everolimus, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable solid tumors refractory to standard therapy.
- Conditions
- Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00949949
- Testing
- everolimus, gemcitabine hydrochloride, cisplatin
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Gallstone, Cholangitis
Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images
The Institute of Imaged-Guided Surgery (IHU Strasbourg) has two clinical Magnetic Resonance Imaging (MRI) scanners, one with a 3T (3 Teslas) magnetic field used for diagnosis, the other with a magnetic field of 1,5T (1,5 Teslas)…
- Conditions
- Gallstone, Cholangitis, Cholangiocarcinoma, Pancreatitis
- Trial name
- BiliFast (NCT03852836)
- Testing
- ultra-rapid acquisition of bile ducts images
- Where
- France
- Volunteers
- 53 people
- Sponsor
- IHU Strasbourg
Bile Duct Obstruction, Klatskin's Tumor
Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture
The overall median survival of nonresectable malignant hilar obstruction in most series has been less than 6 months. Most patients with malignant hilar obstruction present with advanced disease, making palliative endoscopic…
- Trial name
- NCT01125865
- Testing
- SEMS insertion, DLS insertion
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Soon Chun Hyang University
Colorectal Cancer, Pancreatic Cancer
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Trial name
- NCT04421820
- Testing
- BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 220 people
- Sponsor
- Bold Therapeutics, Inc.
Intrahepatic Cholangiocarcinoma
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. Currently, one phase I dose escalation safety study has been completed in China and the United States respectively, both demonstrating excellent…
- Trial name
- NCT07522476
- Testing
- VG2025
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Virogin Biotech Ltd.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gallbladder Cancer, Cholangiocarcinoma
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
The goal of this clinical trial is to evaluate the efficacy and safety of combining Gemcitabine, nab-Paclitaxel, Lenvatinib, and Tislelizumab in adults aged 18-75 years with advanced unresectable biliary tract malignancies…
- Trial name
- GALENT-BT (NCT06963060)
- Testing
- Gemcitabine nab-PaclitaxelLenvatinibTislelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Wei Gong
Morbid Obesity, Vertical Sleeve Gastrectomy
Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma
Increasing rates of highly malignant hepatocellular carcinoma (HCC) and biliary tract cancers (GBTC) observed in Western populations may be related to obesogenic lifestyle factors and their metabolic consequences, such as…
- Conditions
- Morbid Obesity, Vertical Sleeve Gastrectomy, Metabolic Syndrome, Hepatocellular Carcinoma
- Trial name
- METSLIVER (NCT02730611)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bile Duct Cancer
Combined Treatment of Treated Bile Duct Cancer
The study will evaluate the efficacy and safety of envelizumab in combination with sovalteinib in the treatment of treated bile duct cancer, and explore treatment options to improve patient survival, while the study will attempt…
- Trial name
- CHOL (NCT05911425)
- Testing
- envolizumab , sovalteinib
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Liver Cancer
Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma
Our project is a large-scale characterisation of cHCC-CCA will allow us to determine which subsets harbor actionable gene alterations.
- Trial name
- PREMED-CHC (NCT06146127)
- Testing
- phenotyping
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Inserm U955
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.